Brasília – Novo Nordisk identifies Brazil as a priority market for the launch of its oral version of Wegovy, a semaglutide-based treatment for obesity, as the company seeks to expand its footprint in one of the world’s fastest-growing weight management markets. The tablet formulation, already submitted to the National Health Surveillance Agency (ANVISA), is expected to broaden access by offering a more convenient alternative to injectable therapies.

The move comes amid strong demand for GLP-1 drugs in Brazil, where the segment already generates billions in annual sales and continues to expand rapidly. The oral version may also enhance market penetration due to easier administration and potentially lower costs compared to injectables, reinforcing Brazil’s strategic role in Novo Nordisk’s global growth strategy.

Source: Valor Econômico